Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
12.86
-0.27 (-2.06%)
At close: Aug 24, 2026, 4:00 PM EDT
13.07
+0.21 (1.63%)
Pre-market: Aug 25, 2026, 8:02 AM EDT
Candel Therapeutics Employees
Candel Therapeutics had 55 employees as of December 31, 2025. The number of employees increased by 17 or 44.74% compared to the previous year.
Employees
55
Change (1Y)
17
Growth (1Y)
44.74%
Revenue / Employee
n/a
Profits / Employee
-$1,609,655
Market Cap
984.03M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 55 | 17 | 44.74% |
| Dec 31, 2024 | 38 | -4 | -9.52% |
| Dec 31, 2023 | 42 | -34 | -44.74% |
| Dec 31, 2022 | 76 | 11 | 16.92% |
| Dec 31, 2021 | 65 | 24 | 58.54% |
| Mar 31, 2021 | 50 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ardelyx | 489 |
| Wave Life Sciences | 317 |
| Kura Oncology | 260 |
| Geron | 258 |
| Solid Biosciences | 121 |
| Janux Therapeutics | 113 |
| Annexon | 92 |
| Lexicon Pharmaceuticals | 81 |
CADL News
- 8 days ago - Candel Therapeutics price target raised to $12 from $9 at BofA - TheFly
- 12 days ago - Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 12 days ago - Candel Therapeutics Earnings release: Q2 2026 - Filings
- 12 days ago - Candel Therapeutics Quarterly report: Q2 2026 - Filings
- 12 days ago - Candel Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 21 days ago - Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 22 days ago - Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026 - GlobeNewsWire
- 27 days ago - Candel Therapeutics to Present at Canaccord Genuity's 46th Annual Growth Conference in Boston - GlobeNewsWire